Medulloblastomas (MBs) are aggressive brain cancers and represent the most common primary malignant tumour in children. Current treatment protocols involve an intensive regimen of surgery, radiation therapy and chemotherapy, guided by histopathology and risk stratification. Unfortunately, disease relapse proves fatal in 30% of cases, and treatment efficacy is compromised as MB cells develop resistance. Therefore, there is a critical need for more effective and tolerable therapies, especially for the treatment of aggressive MBs associated with a poor prognosis. Lipid metabolism reprogramming, characterized by increased cholesterol synthesis, lipid uptake and the activation of de novo lipogenesis, is a newly identified hallmark of cancers. Cholesterol is an essential structural component of membranes that contributes to membrane integrity and fluidity. Recently, increasing evidence has indicated that cholesterol is a major determinant by modulating cell signalling events governing the hallmarks of cancer. Our research demonstrates there is an overexpression of cholesterol metabolism in group 3 (G3), and group 4 (G4) MB subgroups compared to Sonic Hedgehog (SHH)-MB subgroup. In these tumours, cholesterol metabolism supports cell migration through the Rho-GTPase signalling pathway. Notably, we observed that shifting the culture conditions from 2D to 3D significantly upregulates lipid metabolism. Furthermore, spheroids derived from G3/G4-MBs and SHH-MBs show similar sensitivity to low doses of simvastatin. We validated these findings in a xenograft mouse model, where treatment with low doses of simvastatin led to increased survival time and remarkably, also reduced the metastatic spread of MB cells to the spinal cord. These results suggest that simvastatin holds potential as an adjuvant treatment for patients with medulloblastoma.
Lipid droplets (LDs) are dynamic intracellular organelles traditionally associated with energy storage, which have become increasingly recognised for their versatile roles in cellular metabolism and signalling. In the brain, LDs have emerged as critical regulators in neurodegenerative diseases (NDDs) such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Hereditary Spastic Paraplegia (HSP). LDs contribute to neurodegeneration by influencing lipid metabolism, oxidative stress, and inflammatory responses. For instance, in AD, dysregulated lipid metabolism and impaired Apolipoprotein E 4 (ApoE4) function lead to LD accumulation associated with neuroinflammation and amyloid plaque formation. In PD, interactions between LDs and α-synuclein suggest a potential link between lipid dysregulation and neurotoxicity. Mutations in LD-associated proteins, such as spastin and DDH2 in HSP, highlight the importance of proper LD regulation for neuronal health. While LD accumulation can be protective by mitigating lipotoxicity, prolonged dysregulation can exacerbate NDD pathology. Targeting LD metabolism, through enhancing lipophagy or modulating LD-associated proteins, represents a promising therapeutic avenue. This review highlights the dual roles of LDs in the brain, acting both neuroprotectively and neurotoxically, and the therapeutic potential of targeting LD dynamics for NDD treatment.
Medulloblastomas (MBs) represent the most prevalent malignant solid tumors in kids. The conventional treatment regimen for MBs includes surgical removal of the tumor, followed by radiation and chemotherapy. However, this approach is associated with significant morbidity and detrimental side effects. Consequently, there is a critical demand for more precise and less harmful treatments to enhance the quality of life for survivors. CEP-18770, a novel proteasome inhibitor that targets the 20S subunit, has emerged as a promising candidate, due to its anticancer activity in metastatic solid tumors and multiple myeloma, coupled with an acceptable safety profile. In this study, we aimed to assess the anticancer efficacy of CEP-18770 by employing a variety of MB patient-derived cells and cell lines. Our preclinical investigations revealed that CEP-18770 effectively inhibits proteasome activity and induces apoptosis in MBs cells. Furthermore, we discovered that CEP-18770 and cisplatin, a current component of MB therapy, exhibit a synergistic apoptotic effect. This paper shows that CEP-18770 holds potential as an adjunctive treatment for MB tumors, thereby paving the way for more targeted and less toxic therapeutic strategies.
Medulloblastomas are the most common malignant paediatric brain tumours. High-risk subgroups, including MYC-driven Group 3, Group 4 and aggressive sonic hedgehog tumours, are refractory to current therapies and are associated with poor survival. The gold standard treatment comprises surgical resection with aggressive chemo and radiotherapy leading to severe developmental side effects, highlighting the requirement for novel approaches. Metabolic reprogramming is a crucial component of cancer progression with upregulated lipid metabolism being essential to support cancers survival in nutrient-deprived conditions. Lipid droplets are dynamic intracellular organelles protecting against lipotoxicity, yet their involvement in high-risk Medulloblastoma subgroups remains poorly understood. Here, we use transcriptomics and lipidomics of a panel of Medulloblastoma cells to understand the role of lipid metabolism. Our data shows that high-risk Medulloblastoma cells have increased numbers of lipid droplets and PLIN2 expression. This increased PLIN2 expression was consistent in human tissue microarray analysis. Mechanistically, this is due to an enhanced de novo lipogenesis, cholesterol biosynthesis and lipid uptake. Exogenous delivery of various lipids unveiled an altered maturation of lipid droplets in high-risk cells. Altogether, high-risk Group 3 and Group 4 Medulloblastoma cells use lipid droplets in response to excessive lipid synthesis, presenting a possible novel therapeutic target and prognostic marker.
Introduction: Medulloblastomas (MBs) are a highly aggressive paediatric brain tumour which is very difficult to treat. Lipid metabolism has emerged as a crucial determinant of tumour progression, metastasis and therapy resistance in MBs. Lipid droplets (LDs) are lipid-rich organelles that store neutral lipids; their biology and function remain poorly characterised within MBs. Methods: MB cells from the low-aggressive Sonic hedgehog (SHH) subgroup (DAOY, UW228-2) and the high-aggressive group 3 (G4) and group 4 (G4) subgroups (D458, D283) were treated with 80 μM oleic acid (OA), 50 μM cholesterol (Chol) or a mix to induce LD formation. LDs were isolated, and lipidomic analysis was performed. Results: No lipid species were consistently upregulated across all cell lines under any treatment condition. SHH cell lines exhibited a broad and consistent lipidomic response across all three treatments, resulting in a pronounced triacylglyceride (TAG) and cholesterol ester (CE) storage profile. The more aggressive subgroups exhibited a more selective, OA-driven phenotype, characterised by longer-chain TAG and CE species. Across all cell lines, OA produced the strongest LD expansion and metabolic separation, whereas Chol elicited a more restricted but highly subgroup-specific signature. G3/G4 Chol responses provide evidence for lipid metabolism rewiring, which could be responsible for the more aggressive phenotype. Discussion: These findings demonstrate that MB subtypes not only exhibit distinct basal lipid signatures but also engage in fundamentally different lipid remodelling in response to FA overload. These distinct lipid-handling signatures display metabolic heterogeneity across MB subgroups and suggest subtype-specific vulnerabilities. Overall, these findings position LD remodelling as a potential metabolic target of MB cells.